scholarly journals Current Prospects of Herbal STW 5 Agent in Treatment of Functional Gastrointestinal Diseases

2022 ◽  
Vol 31 (5) ◽  
pp. 61-65
Author(s):  
A. A. Sheptulin
Keyword(s):  
Irritable Bowel Syndrome ◽  
Functional Dyspepsia ◽  
Treatment Efficacy ◽  
Gastrointestinal Diseases ◽  
Mechanisms Of Action ◽  
Current Evidence ◽  
Key Points ◽  
Irritable Bowel ◽  
Functional Gastrointestinal Diseases ◽  
Agent Development

Aim. A review of current therapeutic perspectives of the herbal STW 5 medicine (Iberogast®) in functional gastrointestinal (GI) diseases.Key points. A limited remediation in most common functional GI diseases, functional dyspepsia (FD) and irritable bowel syndrome (IBS), is conditioned by their multifactorial pathogenesis. Meanwhile, most specific medicines only target selected pathogenesis components, thus warranting a multitarget agent development. Such is Iberogast® that acts at variant components of FD and IBS pathogenesis. The article reviews the Iberogast® mechanisms of action and evaluates its treatment efficacy in FD and IBS.Conclusion. The current evidence claims that Iberogast® provides an effective and safe treatment for FD and IBS. 

scholarly journals Colorectal Cancer in Patient with Functional Gastrointestinal Symptoms

2022 ◽  
Vol 31 (5) ◽  
pp. 66-73
Author(s):  
Z. A. Mamieva ◽  
E. A. Poluektova ◽  
A. L. Kovaleva ◽  
O. S. Shifrin ◽  
V. P. Sobolev ◽  
...  
Keyword(s):  
Rectal Adenocarcinoma ◽  
Clinical Manifestations ◽  
Gastrointestinal Symptoms ◽  
Abdominal Ultrasound ◽  
Gastrointestinal Diseases ◽  
Detailed Examination ◽  
Key Points ◽  
Irritable Bowel ◽  
Functional Gastrointestinal Diseases ◽  
Russian Association

Aim. A clinical observation to highlight the importance of detailed examination in patients with functional gastrointestinal symptoms.Key points. A 28-yo female patient was admitted with complains of left ileal pain, abdominal distention and up to 4-day stool delay. The complaints had long been interpreted as clinical manifestations of irritable bowel syndrome. No significant abnormalities were revealed in outpatient check-up (general and biochemical blood panels, stool test, abdominal ultrasound, oesophagogastroduodenoscopy). Colonoscopy was performed on admission, with diagnosis of rectal adenocarcinoma. The patient had a prompt surgical intervention, repeated courses of polychemotherapy and is currently followed by an oncologist and coloproctologist. No relapse signs have been reported.Conclusion. Patients with the complaints satisfying the Rome Criteria Revision IV for functional gastrointestinal diseases should have a thorough examination as per recommendations of the Russian Gastroenterological Association and Russian Association of Coloproctologists. 

scholarly journals An Integrated Gut Microbiota and Network Pharmacology Study on Fuzi-Lizhong Pill for Treating Diarrhea-Predominant Irritable Bowel Syndrome

2021 ◽  
Vol 12 ◽  
Author(s):  
Zhang Zhen ◽  
Lin Xia ◽  
Huang You ◽  
Zhou Jingwei ◽  
Yang Shasha ◽  
...  
Keyword(s):  
Irritable Bowel Syndrome ◽  
Gut Microbiota ◽  
Clinical Effect ◽  
Gastrointestinal Diseases ◽  
The Body ◽  
Network Pharmacology ◽  
Ifn Γ ◽  
Irritable Bowel ◽  
D Model ◽  
Functional Gastrointestinal Diseases

Diarrhea-predominant irritable bowel syndrome (IBS-D) is one of the most common chronic functional gastrointestinal diseases with limited treatments. Gut microbiota play an important role in chronic gastrointestinal diseases. In traditional Chinese medicine (TCM), Spleen–Yang deficiency (SYD) is one of the root causes of IBS-D. Fuzi-Lizhong pill (FLZP) is well known for its powerful capacity for treating SYD and has a good clinical effect on IBS-D. However, the mechanism of FLZP on the gut microbiota of IBS-D has not been fully clarified. Our present study aimed to reveal the mechanism of FLZP regulating gut microbiota of IBS-D. The body mass, CCK, MTL, and Bristol fecal character score were used to verify the establishment of the IBS-D model. IL-6, TNF, IL-1β, and IFN-γ were crucial targets screened by network pharmacology and preliminarily verified by ELISA. Eighteen gut microbiota were important for the treatment of IBS-D with FLZP. Bacteroidetes, Blautia, Turicibacter, and Ruminococcus_torques_group were the crucial gut microbiota that FLZP inhibits persistent systemic inflammation in the IBS-D model. Lactobacillus is the crucial gut microbiota that FLZP renovates intestinal immune barrier in the IBS-D model. In summary, FLZP can affect bacterial diversity and community structures in the host and regulate inflammation and immune system to treat IBS-D.

Irritable bowel syndrome at young age: Salofalk treatment efficacy

2018 ◽  
Vol 0 (4) ◽  
pp. 67-73
Author(s):  
A. E. Dorofeyev ◽  
M. M. Rudenko ◽  
Yu. V. Zhigal
Keyword(s):  
Irritable Bowel Syndrome ◽  
Treatment Efficacy ◽  
Young Age ◽  
Irritable Bowel
Sign in / Sign up

Export Citation Format

Share Document